Snyder, 1972 - Google Patents
Catecholamines in the brain as mediators of amphetamine psychosisSnyder, 1972
- Document ID
- 9055392650867296201
- Author
- Snyder S
- Publication year
- Publication venue
- Archives of general psychiatry
External Links
Snippet
Amphetamine psychosis appears to be a fruitful experimental model of paranoid schizophrenia or paranoid state. A variety of animal and human studies suggest that neurochemical mediation of certain behavioral effects of amphetamine in animals may …
- 206010061920 Psychotic disease 0 title abstract description 151
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Snyder | Catecholamines in the brain as mediators of amphetamine psychosis | |
| Snyder | Amphetamine psychosis: a" model" schizophrenia mediated by catecholamines | |
| Snyder et al. | Drugs, Neurotransmitters, and Schizophrenia: Phenothiazines, amphetamines, and enzymes synthesizing psychotomimetic drugs aid schizophrenia research. | |
| Chiarello et al. | The use of psychostimulants in general psychiatry: a reconsideration | |
| Rapeli et al. | Cognitive function during early abstinence from opioid dependence: a comparison to age, gender, and verbal intelligence matched controls | |
| Ellis et al. | The pharmacology of human working memory | |
| Goldmann Gross et al. | Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies: a spectrum of disease | |
| Edwards et al. | Controlled trial of sulpiride in chronic schizophrenic patients | |
| Baldessarini | American biological psychiatry and psychopharmacology 1944–1994 | |
| Davis et al. | Research in endorphins and schizophrenia. | |
| Spasova et al. | Impact of nicotine on cognition in patients with schizophrenia: a narrative review | |
| Ashby Jr | The modulation of dopaminergic neurotransmission by other neurotransmitters | |
| Pottash et al. | Psychiatric complications of antihypertensive medications | |
| Persico et al. | Parkinsonian patients report blunted subjective effects of methylphenidate. | |
| Onasanwo et al. | Antidepressant-like potentials of Buchholzia Coriacea seed extract: involvement of monoaminergic and cholinergic systems, and neuronal density in the hippocampus of adult mice | |
| Karczmar | Basic phenomena underlying novel use of cholinergic agents, anticholinesterases and precursors in neurological including peripheral and psychiatric disease | |
| Kłys et al. | Death of a female cocaine user due to the serotonin syndrome following moclobemide–venlafaxine overdose | |
| Ramasubbu et al. | A neuroendocrine study of serotonin function in depressed stroke patients compared to non depressed stroke patients and healthy controls | |
| Ziervogel | Selective serotonin re-uptake inhibitors for children and adolescents | |
| Lare et al. | Sildenafil and erectile dysfunction | |
| Negrete et al. | Cannabis and schizophrenia: an overview of the evidence to date | |
| Cui et al. | The effects of atropine on changes in the sleep patterns induced by psychological stress in rats | |
| Waters et al. | Olanzapine-associated new-onset atrial fibrillation | |
| Acton | Amphetamines—Advances in Research and Application: 2013 Edition | |
| Mittel | Parkinson's disease: Overview and current abstracts |